OptimizeRx Corporation (OPRX)

OptimizeRx reported strong Q4 and full-year 2025 financial results, exceeding analyst estimates, but cautious 2026 revenue guidance triggered a stock sell-off. Mary Varghese Presti was appointed to the Board of Directors. The company collaborated with Experian to enhance privacy-safe identity resolution in healthcare marketing. OptimizeRx expanded its in-workflow point-of-care network through new partner agreements. The company reported a revenue increase for Q3 2025 and increased its fiscal year 2025 guidance. The stock experienced a significant sell-off due to cautious 2026 guidance and market shifts.

No specific information detailing the demand seasonality for OptimizeRx Corp.'s products and services was found in the provided search results. The company's fiscal year aligns with the calendar year, with quarterly earnings reports, but direct mentions of seasonal demand fluctuations are not available.

OptimizeRx Corp. is a digital healthcare technology company that connects life sciences organizations, healthcare professionals, and patients through its digital health platform. The platform offers solutions such as the Dynamic Audience Activation Platform (DAAP), Micro-Neighborhood Targeting (MNT), Profiler, Banner Messages, Media Execution Solutions, Pharmacy Alerts, and Financial Messaging Solutions. The company was founded in 2006.

OptimizeRx Corp. primarily operates within the United States healthcare market and is headquartered in Waltham, Massachusetts. The company is expanding its point-of-care network within the U.S. and exploring opportunities to extend its digital health network into new regions.

No specific information regarding OptimizeRx Corp.'s brand reputation or any events that have significantly affected its reputation in the past year was found in the provided search results. The available news primarily focuses on financial performance, strategic partnerships, and product developments.

OptimizeRx Corp. has a diverse ownership structure, including institutional, retail, and individual investors. Approximately 47.50% to 57.91% of the company's stock is held by institutional investors, 6.46% by insiders, and 10.41% to 35.64% by public companies and individual investors. Major institutional owners include Whetstone Capital Advisors, LLC, BlackRock, Inc., and Vanguard Group Inc, among others.